Literature DB >> 17415046

Tuberculosis manifested by immune reconstitution inflammatory syndrome during HAART.

Wan Beom Park1, Pyoeng Gyun Choe, Jae Hyun Jo, Sung-Han Kim, Ji Hwan Bang, Hong Bin Kim, Nam Joong Kim, Myoung-don Oh, Kang Won Choe.   

Abstract

The proportion of tuberculosis manifested by immune reconstitution inflammatory syndrome (IRIS) after HAART has not been established. We describe the incidence and clinical features of tuberculosis manifested by IRIS after HAART in an intermediate tuberculosis burden area. The findings suggest that a significant proportion of the tuberculosis occurring early after starting HAART is manifested by IRIS.

Entities:  

Mesh：

Year:  2007        PMID： 17415046     DOI： 10.1097/QAD.0b013e3280f7751f

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

2.  Impact of the immune reconstitution inflammatory syndrome (IRIS) on mortality and morbidity in HIV-infected patients in Mexico.

Authors:  Irma Hoyo-Ulloa; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramirez; Arturo Galindo-Fraga; María Eugenia Pérez-Aguinaga; Juan G Sierra-Madero
Journal:  Int J Infect Dis       Date:  2011-04-13       Impact factor: 3.623

3.  Immune reconstitution inflammatory syndrome: incidence and implications for mortality.

Authors:  Richard M Novak; James T Richardson; Kate Buchacz; Joan S Chmiel; Marcus D Durham; Frank J Palella; Andrea Wendrow; Kathy Wood; Benjamin Young; John T Brooks
Journal:  AIDS       Date:  2012-03-27       Impact factor: 4.177

4.  Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection.

Authors:  Chad J Achenbach; Robert D Harrington; Shireesha Dhanireddy; Heidi M Crane; Corey Casper; Mari M Kitahata
Journal:  Clin Infect Dis       Date:  2011-11-17       Impact factor: 9.079

5.  Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda.

Authors:  Joshua Baalwa; Harriet Mayanja-Kizza; Moses R Kamya; Laurence John; Andrew Kambugu; Robert Colebunders
Journal:  Afr Health Sci       Date:  2008-09       Impact factor: 0.927

6.  Immune reconstitution inflammatory syndrome.

Authors:  Stephen D Lawn; Robin Wood
Journal:  Lancet Infect Dis       Date:  2010-12       Impact factor: 71.421

7.  Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART.

Authors:  Suman Karmakar; Surendra K Sharma; Richa Vashishtha; Abhishek Sharma; Sanjay Ranjan; Deepak Gupta; Vishnubhatla Sreenivas; Sanjeev Sinha; Ashutosh Biswas; Vinay Gulati
Journal:  Clin Dev Immunol       Date:  2010-12-01

8.  Antiretroviral treatment-associated tuberculosis in a prospective cohort of HIV-infected patients starting ART.

Authors:  William Worodria; Marguerite Massinga-Loembe; Harriet Mayanja-Kizza; Jane Namaganda; Andrew Kambugu; Yukari C Manabe; Luc Kestens; Robert Colebunders
Journal:  Clin Dev Immunol       Date:  2010-12-08

Review 9.  Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis.

Authors:  Lifang Li; Jianqiang Li; Chunwei Chai; Tanzhen Liu; Pingping Li; Mengrui Qu; Hui Zhao
Journal:  Int J Clin Exp Pathol       Date:  2021-06-15

Review 10.  Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy.

Authors:  Stephen D Lawn; Robert J Wilkinson; Marc C I Lipman; Robin Wood
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.